The scene
Picture the RA/QA lead in a dual-market product review before management review. The company sells or plans to sell in both the United States and Canada, but FDA and Health Canada evidence is scattered across different links and owners.
A single PMS file can work if it keeps jurisdiction labels visible. It fails when one public signal is treated as a universal answer.
Dual-market comparison map
| File row | What to record |
|---|---|
| Jurisdiction | United States, Canada, or cross-market context. |
| Source | FDA, Health Canada, MDALL, MDEL, recall, alert, or internal record. |
| Signal type | Product-family context, licence/listing clue, recall, complaint, supplier, service, or label issue. |
| Internal owner | RA/QA, supplier quality, distributor, importer, operations, legal, clinical, or leadership. |
| Decision boundary | What remains open for qualified review. |
How to avoid overclaiming
Do not use a Canadian licence clue to answer a United States inspection question. Do not use an FDA adverse-event signal to answer a Canadian distributor-duty question. Each source should stay attached to its jurisdiction and limitation.
The evidence map should help the reviewer ask better questions, not compress two regulatory systems into one shortcut.
Source ledger
What it can tell you
Canadian public recall and safety-alert records that can trigger review questions for a device or product family.
What it cannot decide
Recall applicability, importer duty, complaint disposition, reportability, or distribution action for a specific company.
What it can tell you
Public active medical device licence records for Class II, III, and IV medical devices in Canada.
What it cannot decide
Licence reliance, distributor readiness, importer duty, label acceptability, or quality-system adequacy.
What it can tell you
Public establishment licence records that can inform distributor, importer, or establishment-role questions.
What it cannot decide
Whether a specific organization may perform a role for a specific transaction, product, or commercial arrangement.
Frequently asked questions
Can one PMS file serve both FDA and Health Canada questions?
It can organize both sets of evidence if the file keeps jurisdiction, source limits, and qualified-review decisions separate.
What is the first useful output?
A dual-market PMS comparison map with public source links, internal record owners, jurisdiction labels, and open review questions.
Need one FDA and Health Canada PMS evidence map?
Send the product family, target jurisdictions, and current review question. We can scope a dual-market evidence map for qualified review.
Reader feedback
Useful pages should feed the next topic choices. Leave a signal or a short comment.